key: cord-0748048-bouatdyd
authors: Choi, Yohan; Jeon, Hayce; Brännström, Mats; Akin, James W.; Curry, Thomas E.; Jo, Misung
title: The ovulatory up-regulation of ACE2, a receptor for SARS-COV-2, in dominant follicles of the human ovary.
date: 2021-08-11
journal: Fertil Steril
DOI: 10.1016/j.fertnstert.2021.08.009
sha: 7121c7631c48cca78f309ae872b63c78b6c9056b
doc_id: 748048
cord_uid: bouatdyd

Objective To determine the temporal expression of ACE2, a receptor for SARS-COV-2, in dominant follicles across the periovulatory period in women and the regulatory mechanisms underlying ACE2 expression in human granulosa/lutein cells (hGLC). Design Experimental prospective clinical study and laboratory-based investigation. Setting University Medical Center and private IVF center. Patients Thirty premenopausal women undergoing surgery for tubal ligation and 16 premenopausal women undergoing IVF. Intervention (s) Administration of hCG and harvesting of preovulatory/ovulatory follicles by timed laparoscopy and collection of granulosa/lutein cells and cumulus cells at the time of oocyte retrieval. Main Outcome Measures Expression and localization of ACE2 in granulosa cells and dominant follicles collected across the periovulatory period of the menstrual cycle and in hGLC using qPCR, immunoblotting, and immunohistochemistry. Results ACE2 expression (mRNA and protein) is up-regulated in human ovulatory follicles after hCG administration. ACE2 expression was higher in cumulus cells than granulosa cells. hCG increased the expression of ACE2 in primary hGLC cultures, but the increase was inhibited by both RU486 (an antagonist for progesterone receptor and glucocorticoid receptor) and CORT125281 (a selective glucocorticoid receptor), but not by AG1478 (an EGF-receptor tyrosine kinase inhibitor) or by dexamethasone. Conclusions The hormone-regulated expression of ACE2 in granulosa cells suggests a potential role of ACE2 in the ovulatory process. These data also implicate the possible impact of COVID-19 in a vital cyclic event of ovarian function, thus women's overall reproductive health. However, SAR-COV-2 infection in ovarian cells in vivo or in vitro has yet to be determined.

Since the beginning of the COVID-19 pandemic, heightened attention has been given to angiotensin-26 converting enzyme 2 (ACE2) as it acts as an entry receptor for SARS-COV-2, a novel strain of the virus 27 that causes COVID-19 (1) . However, this role of ACE2 in the viral cellular entry is in contrast to its 28 original reported function as a component of the renin-angiotensin system (RAS). 29

Initially, ACE2 was discovered as a zinc metalloprotease that is capable of catalyzing angiotensin I 30 (Ang I) and angiotensin II (Ang II) to angiotensin-(1-9) and angiotensin-(1-7), respectively (2, 3) . ACE2 31 displays high homology to human angiotensin-converting enzyme (ACE) (2, 4) . ACE is well known for its 32 ability to convert inactive angiotensin Ang I into the functionally active hormone Ang II (5) . The best-33 elucidated actions of Ang II include vasoconstriction, stimulation of aldosterone and vasopressin 34 secretion, vascular smooth muscle proliferation, and renal tubular sodium reuptake, thereby regulating 35 body fluid volume, electrolyte balance, and arterial pressure (6, 7) . However, these effects of Ang II are 36 tightly controlled by ACE2 whose role is to limit locally available Ang II concentration by rapidly 37

hydrolyzing Ang II to Ang-(1-7) (8) . Ang-(1-7) has also been shown to enhance vasodilation and exert 38

anti-oxidative, anti-inflammatory, and pro-resolution effects, likely through the activation of the G 39 protein-coupled receptor MAS1 (MAS1 Proto-Oncogene) (9) . Therefore, ACE2 functions as a key 40 counter-regulatory enzyme in the RAS. In addition to the role in the RAS, ACE2 can cleave other peptide 41 substrates such as neurotensin, kinetensin, des-Arg bradykinin, and Apelins (-13, -17, and -36) (2, 10) . 42

Besides these enzymatic functions, ACE2 was identified as a binding site for human coronavirus 43

HCoV-NL63 and the human severe acute respiratory syndrome coronaviruses, SARS-COV and SARS-44 COV-2 (11) . The spike proteins on the surface of SARS coronaviruses bind to ACE2 on its target cells, 45

initiating the virus-cell membrane fusion and ultimately resulting in viral replication inside the host cells 46 (11) . 47 ACE2 mRNA was detected in most human tissues examined, yet the detection of ACE2 protein was 48 limited in several tissues, including the lung, kidney, heart, and intestine (12) . Specifically, the abundant 49 ACE2 expression was localized to lung alveolar epithelial cells, enterocytes of the small intestine, and 50 vascular endothelial cells of the heart and kidney (13) . The testis was also among the tissues that 51 expressed high levels of ACE2 (mRNA and protein) (14) . In contrast, little is known about the expression 52 pattern of ACE2 in the human ovary. Even two public databases for protein expression profiles (Human 53 protein atlas and GeneCards) contradict each other; the latter suggests the high expression of ACE2, 54

whereas the former indicates little to no expression. Meanwhile, there were a limited number of studies 55 documenting the expression of ACE2 in the ovary of animals (15, 16) . Pereira et al. have reported that 56 ACE2 expression was increased in theca/interstitial layer of the immature rat ovary when administrated 57 J o u r n a l P r e -p r o o f with eCG to stimulate follicle development (16) . In the bovine ovary, the follicular levels of ACE2 58 mRNA were transiently downregulated during the ovulatory period (15) . As a proxy indicator of ACE2 59 expression, Ang II and Ang (1-7) were reported to be present in the ovary of multiple species (15) (16) (17) (18) . 60

Previous studies showed that Ang II and Ang-(1-7) stimulated steroid hormone production and enhanced 61 ovulation and oocyte maturation in rats, rabbits, and cattle (17, (19) (20) (21) (22) . Similarly, Ang-(1-7) was detected 62 in the follicular fluid of women undergoing IVF procedure; this heptapeptide level was correlated 63 clinically with the oocyte maturation rate (23) . 64

The ovary undergoes constant remodeling and cyclic ovulation that requires precisely controlled 65 angiogenesis and an acute inflammatory response {reviewed in (24)}. Given that ACE2 has been shown 66

to play an important role in both angiogenesis and inflammatory responses, it is conceivable that this 67 enzyme is expressed and involved in these processes in the human ovary. Moreover, accumulating 68 evidence indicates that SARS-COV-2 can infect multiple organs including the ovary (25) , but the long-69 term health impact of COVID-19 is yet to be determined. Therefore, it is critically important to assess the 70 expression of ACE2 in the human ovary. In the present study, we sought to: 1) characterize the expression 71 pattern of ACE2 (mRNA and protein) using dominant follicles collected before the LH surge and 72 throughout the periovulatory period from naturally cycling women with ovulation induced by hCG and 2) 73 dissect the cellular regulatory mechanism controlling ACE2 expression using primary human 74 granulosa/lutein cells. 75 J o u r n a l P r e -p r o o f

Unless otherwise noted, all reagents were purchased from Sigma Chemical Co. or Thermo Fisher 78

The protocol using human tissues was approved by the Human Ethics Committee of the Sahlgrenska 81

Academy at the University of Gothenburg, and all patients had given their informed written consent 82 before participating. Whole follicles were collected from patients across the periovulatory period as 83 previously described (26) . Women (age 30-38 yr) exhibiting regular menstrual cycles and had not taken 84 hormonal contraceptives for at least 3 months prior to their enrollment in the study underwent 85 laparoscopic sterilization. Women were monitored by transvaginal ultrasound for 2 to 3 menstrual cycles 86 before surgery to ascertain cycle regularity and to monitor the growth of a dominant follicle during the 87 follicular phase. These patients were divided into 4 groups: pre-, early-, late-and post-ovulatory phases. 88

In the preovulatory group, surgery was performed when the follicle reached >14 mm and ≤17.5 mm in 89 diameter prior to the endogenous LH surge. These patients were not given hCG. The remaining women 90 were given recombinant hCG (Ovitrelle, 250 µg) and were divided into three groups; early-ovulatory 91 (surgery between 12 to 18h post-hCG) and late-ovulatory (surgery between 18 to 34h post-hCG). To 92 confirm that these patients followed a normal hormonal pattern before the LH surge or after hCG 93 administration, blood samples were taken at surgery and measured for serum progesterone and estradiol 94 (27) . The whole intact follicle/early corpus luteum was removed using laparoscopic scissors and 95 processed for either immunohistochemical or gene expression analysis. The follicle was bisected, and 96 mural granulosa cells were gently scraped off from the interior of the follicle by small tissue forceps. For 97 the gene expression study, the follicular fluid and cell suspension were combined and centrifuged at 500 x 98 g to pellet and collect granulosa cells. For the immunohistochemistry study, dominant follicles were fixed 99 as described below. 100

Human granulosa/lutein cells were obtained from aspirates of IVF patients. The collection protocol 102 The experiments with hGLC were carried out as described previously (26, 28) . Briefly, immediately after 108 J o u r n a l P r e -p r o o f retrieval of cumulus oocyte complexes, the remaining cells in aspirates were subjected to percoll gradient 109 centrifugations to remove red blood cells. The cells from patients aged 24-40 with non-ovarian etiologies 110 (e.g., male factor and egg donor) were used. The isolated cells were first examined under the microscope 111 for their morphology, counted, and resuspended with OptiMEM media supplemented with 10% fetal 112 bovine serum and antibiotic-antimycotic and then seeded onto culture plates (2.5 × 10 5 cells/ml). The 113 cells were acclimatized for 6 days, changing media every 24 h. At the end of acclimation, the hGLCs 114 were treated with or without hCG (1 IU/ml) in the absence or presence of various reagents described in 115 the results section and cultured in OptiMEM media supplemented with antibiotic-antimycotic cultured for 116 stated hours. 117

Follicles were fixed in 4% formaldehyde, embedded in paraffin, and sectioned (7 μm). 119

Shared Resource Facility at the University of Kentucky as previously described (28) . Briefly, heat-121 induced epitope retrieval was performed in a Biocare Medical Decloaking chamber utilizing Dako's low 122 pH Target Retrieval Solution. Primary antibody incubation was carried out at 4 o C overnight for ACE2 123 (Sigma-Aldrich, HPA000288, 1:200 dilution) and for 2 h at room temperature for PECAM1 (Roche 124

Diagnostics, JC70 monoclonal antibody, pre-dilute), respectively. Rabbit IgG was used in place of 125 primary antibodies as a negative control. The antibody staining was detected using an appropriate 126 Immpress alkaline phosphatase kit and Vector Red AP chromogen (Vector Laboratories). 127

The levels of mRNA for ACE2 was measured using a methodology previously described (28) . Briefly, 129 total RNA was isolated from granulosa cells using an RNeasy mini kit (Qiagen). The synthesis of the 130 first-strand cDNA was performed by reverse transcription of 500 ng total RNA using superscript III. The 131 levels of mRNA for genes examined were measured by qPCR using Brilliant 3 Ultra-Fast SYBR green 132 (Stratagene). Oligonucleotide primers corresponding to ACE2 were designed using Primer3 software (5'-133 GGTGGGAGATGAAGCGAGAG-3', 5'-ACATGGAACAGAGATGCGGG-3'). The relative abundance 134 of the target transcript was normalized to internal reference genes (GAPDH for in vivo sample and 135 RNA18S5 for in vitro sample) as previously described (26, 28) and calculated according to the 2 -ΔΔCT 136 method (29) . 137

Nuclear extracts were isolated from cultured cells, denatured, run on a 10% polyacrylamide gel, and 139 then transferred onto a nitrocellulose membrane as described previously (28) . The membrane was 140 incubated overnight at 4°C in 5% skim milk in Tris-buffered saline including 0.1% Tween-20 solution 141 J o u r n a l P r e -p r o o f containing primary antibodies against ACE2 (Sigma-Aldrich, HPA000288, 1:100 dilution) and ACTB 142 (Santa Cruz Biotechnology, sc-47778, 1:1,000 dilution). The blots were incubated with the respective 143 secondary HRP-conjugated antibody for 1 h at room temperature. Peroxidase activity was visualized 144 using the SuperSignal®West Pico Chemiluminescent Substrate (Pierce Chemical). 145

All data are presented as means ± SEM. Data were tested for homogeneity of variance by Levene's 147 test, and log transformations were performed as appropriate. Paired sample t-test or analysis of variance 148 (ANOVA) were used to test differences in levels of mRNA for ACE2 between cell types or across the 149 time of tissue collection, time of culture, or among treatments in vitro, as appropriate. If the test revealed 150 significant effects, the means were compared by Duncan's test, with p < 0.05 considered significant. 151 J o u r n a l P r e -p r o o f RESULTS 152

To determine whether ACE2 is expressed and regulated in human preovulatory follicles during the 154 ovulatory period, the levels of mRNA for ACE2 were assessed in granulosa cells isolated from dominant 155 follicles collected during the pre-, early, late, and post-ovulatory period. The levels of mRNA for ACE2 156 were markedly increased in granulosa cells during both early and late ovulatory phases (> 40-fold) 157 compared to those obtained before hCG administration (Fig. 1 ). After ovulation, the levels of ACE2 158 mRNA in granulosa cells of post-ovulatory follicles were similar to those of dominant follicles collected at 159 the early and late ovulatory phases, but higher than those of dominant follicles collected before hCG 160 administration (Fig.1A) . Next, to determine whether ACE2 is also expressed in cumulus cells of ovulatory 161 follicles, we collected granulosa cells and cumulus cells from women undergoing IVF procedures at the 162 Fig. 2D ). Beside granulosa and theca cell layers, intense staining for ACE2 was detected throughout 177 the stroma layer of late ovulatory follicles (Fig. 2D, wavy arrow) . After ovulation, the staining for ACE2 178 was persistent in both granulosa-and theca-lutein cells of the post-ovulatory follicle as well as in the 179 stroma layer, showing intense staining in some, but not all follicular cells (arrows and wavy arrows in Fig.  180   2E&F) . 181

In the ovary, endothelial cells and leukocytes infiltrate into the granulosa and theca cell layer of 182 ovulating follicles during follicle transformation into the corpus luteum (30) . With the current finding that 183 a subpopulation of cells in the granulosa and theca cell layer exhibited intense staining for ACE2, we 184 questioned whether ACE2 was expressed in infiltrating endothelial cells and leukocytes. Therefore, the 185 serial sections of late and post-ovulatory follicles used to detect ACE2 protein were evaluated for 186 PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) known to be expressed on the surface of 187 endothelial cells, platelets, monocytes, neutrophils, and some types of T-cells (31) . As expected, the 188 immunopositive staining for PECAM1 was localized to endothelial cells lining various types of blood 189 vessels and leukocytes inside blood vessels surrounding the ovulatory and postovulatory follicles (Fig. 3A  190 & E). PECAM1 staining was also detected in endothelial cells located between the granulosa and theca 191 interna layer throughout the late ovulatory follicle (Fig. 3B, arrows) and theca lutein layer of the post-192 ovulatory follicle (Fig. 3F, arrows) . However, this endothelial cell and leukocyte expression of PECAM1 193 in the ovulatory and post-ovulatory follicles was not co-localized to the distribution of ACE2 (arrows in 194 

To investigate the cellular mechanisms underlying the marked up-regulation of ACE2 expression 197 in periovulatory follicles after hCG administration in vivo, we utilized primary human granulosa/lutein 198 cells (hGLC) that were acclimated in cultures for 6 days without any hormone treatments to regain hCG 199 responsiveness. As shown in Fig. 4A , we found that hCG treatment increased the expression of ACE2, 200 both at the levels of mRNA and protein compared to those in control samples, similar to those observed 201 during the peri-ovulatory period of the menstrual cycle. 202

Next, to determine whether the hCG-induced increases in ACE2 expression were mediated by key 203 ovulatory mediators such as the EGF-receptor signaling, P4/PGR, or glucocorticoids/NR3C1, the hGLCs 204 were treated with or without hCG in the absence or presence of AG1478 (an EGF-receptor inhibitor), 205 RU486 (a dual antagonist for progesterone receptor and glucocorticoid receptor), CORT123567 (a 206 selective NR3C1 inhibitor), or dexamethasone (a synthetic glucocorticoid). As expected, hCG increased 207 ACE2 expression, but the hCG-induced increases were completely abolished by RU486 at both 24 and 36 208 h (Fig. 4B) . CORT125281 treatment also resulted in a partial reduction of hCG-induced ACE2 expression 209 at both time points. In contrast, neither AG1478 nor dexamethasone had effects on basal and hCG-induced 210 In women throughout their reproductive age, the ovary undergoes a series of cyclic changes 213 during the menstrual cycle, with the culmination being ovulation. The preovulatory LH surge initiates 214 these cyclic changes by inducing the expression of specific genes. The encoded products of these 215 ovulatory genes exert their biological actions to bring about necessary cellular and extracellular changes 216 required for ovulation and corpus luteum (CL) formation. In the present study, we revealed that the 217 expression of ACE2, an enzyme with carboxypeptidase activity and a primary receptor for SARS-COV-2, 218 is rapidly and dramatically induced after hCG administration in dominant follicles obtained from 219 naturally cycling women throughout the periovulatory period. Using the primary hGLC model that can 220

recapitulate key ovulatory changes in gene expression, this study further provided experimental evidence 221 that the ovulatory induction of ACE2 expression was mediated by hCG and hCG-induced steroid 222 hormones, progesterone and glucocorticoid, in ovulatory follicles. Noteworthy is also our finding of the 223 higher expression of ACE2 in cumulus cells than granulosa cells collected immediately prior to ovulation. 224

Together, not only does this novel information suggest the potential involvement of ACE2 as a critical 225 enzyme for the LH surge-induced cyclic events of ovulation, cumulus expansion, oocyte maturation, and 226 luteal formation, but also implicate the possible impact of COVID-19 in vital cyclic ovarian functions, 227 thus women's overall reproductive health. 228

Our comprehensive in vivo study is novel in that these data are: 1) the first report documenting 229 the ovulatory induction of ACE2 expression in naturally cycling women and 2) the only report showing 230 the dramatic and rapid up-regulation after ovulatory induction among any species studied so far. In cattle, 231 ACE2 mRNA levels were initially down-regulated in granulosa cells after the LH surge induction, but 232 then increased back to the preovulatory level at 24 h after GnRH injection, while no changes were 233 observed in thecal levels of ACE2 mRNA throughout the periovulatory period (15) . No significant 234 changes in ACE2 expression pattern was observed in preovulatory follicles obtained before and 235 throughout the ovulatory period in the non-human primate ( Supplementary Fig. 1)(32) . In the mouse 236 ovary, ACE2 mRNA profile showed low abundance without a clear pattern throughout follicular 237 development and the ovulatory period (http://okdb.appliedbioinfo.net, Supplementary Fig. 2) . Therefore, 238

our data indicate that the dramatic up-regulation of ACE2 expression is specific to human ovulatory 239 follicles and further points to the differences in specific mechanisms underlying the ovulatory process 240 among different species. Of note, in the present study, hCG (rhCG for in vivo and urinary hCG for in 241 vitro studies) was given to patients to mimic the endogenous LH surge. This was to control exactly when 242 the ovulatory trigger was initiated in individual patients. Therefore, it remains to be determined whether 243 the endogenous LH surge and hCG administration would exert the same effect on ACE2 expression. 244

Another intriguing finding is the unique localization pattern for ACE2 protein observed in human 245 ovulatory follicles. The initial induction of ACE2 staining was localized evenly throughout the granulosa 246 and theca cell layer during the early ovulatory phase, and then, the staining became more intense and 247 progressively more sporadic among cells when the dominant follicle progressed toward ovulation and 248 transformed into the CL. The uneven, localized staining of ACE2 did not appear to be in non-follicular 249 cells such as endothelial cells or leukocytes when compared to PECAM1 staining pattern in serial 250 sections of the same follicle. Consistent with this finding, qPCR analysis of ACE2 mRNA levels showed 251 little to undetectable levels of ACE2 mRNA in leukocytes compared to granulosa cells (Supplementary 252 To explore the cellular mechanism underlying ovulatory ACE2 expression, we have utilized 260 granulosa cells pooled from multiple follicles of each patient obtained during IVF oocyte retrieval. 261

Despite the potential limitations of pooling granulosa cells that may have come from different 262 development stages of follicles, these cells (hGLC) increased the expression of genes involved in the 263 ovulatory process, including PGR and EGF-like peptides and the production of progesterone and 264 prostaglandins in response to hCG (28) . Similarly, consistent with the in vivo expression pattern, hCG 265 stimulated ACE2 expression in hGLC in vitro. Furthermore, this induction was completely inhibited by 266 RU486, a dual antagonist for PGR and NR3C1 and partially by CORT125281, a selective antagonist for 267 NR3C1. Our pilot study showed that hCG increased NR3C1 expression and cortisol production in hGLCs 268 ( Supplementary Fig. 4) . These data, taken together, indicate that the up-regulated expression of ACE2 was 269 mediated by the actions of progesterone and glucocorticoids in granulosa cells of the ovulatory follicle. 270

promoted ACE2 expression in the endometrial stroma of both humans and mice (34) . Meanwhile, the 272 existing data on the regulation of ACE2 expression by glucocorticoids or its receptor appear to be 273 dependent on cell types and models tested (35, 36) . Therefore, our findings of the regulatory mechanisms 274 involved in ACE2 expression provide new insights into the ovulatory process and valuable data that may 275 be useful in understanding SARS-COV-2 infection in reproductive-age women. 276

In normal physiology, ACE2 is best known for its ability to hydrolyze Ang II to Ang (1-7) (8, 9) . 277 Therefore, the marked increases in ACE2 expression could mean the shift in the balance between Ang II 278 and Ang-(1-7), reducing Ang II levels while increasing Ang-(1-7). Both Ang II and Ang-(1-7) are present 279 in the follicular fluid collected at the time of IVF in women (18) . Studies using animal models have 280

shown that Ang II and Ang-(1-7) stimulated steroid production, regulated blood flow, and promoted 281 oocyte maturation and ovulation (20, (37) (38) (39) . Therefore, the current findings showing rapid induction of 282 ACE2 expression in human ovulatory follicles and high expression of ACE2 in cumulus cells support the 283 notion that Ang II/ACE2/Ang-(1-7) is likely involved in cumulus expansion, oocyte maturation, and the 284 ovulatory process in the human ovary. 285

With the current global challenge with COVID-19, our findings take on another level of 286 significance since ACE2 serves as a primary entry receptor for SARS-CO-2. A recent study has reported 287 ACE2 expression in oocytes, cumulus, and granulosa cells collected from patients at the time of IVF 288 procedure (40) . In that study, the expression of TMPRSS2, CD147, and CTSL was also documented in 289 these ovarian cells as factors involved in SARS-COV-2 infection (40) . Therefore, our current findings 290

showing the rapid and dramatic induction of ACE2 expression, together with the findings from the 291 previous study (40) , offer a compelling possibility that the ovary could be a target of SARS-COV-2, 292 particularly vulnerable during the periovulatory period. In the scenario of SARS-COV-2 infection in the 293 ovary, this virus could elicit negative impacts on female fertility, not only by blocking the physiological 294 action of ACE2 necessary for oocyte maturation, ovulation, and CL formation but also destroying a 295 mature oocyte and ovulatory follicle. In support of these possibilities, Orvieto et al. (41) reported that the 296 proportion of top-quality embryos was significantly reduced in couples undergoing consecutive IVF 297 cycles after recovering from COVID-19 infection compared to that obtained before the infection. 298

Therefore, it will be vital to give adequate attention to the reproductive health to women who had 299 COVID-19 and appropriate precautions and screening to women seeking IVF treatments. Once more data 300 and information becomes available, it will be of great interest to assess the impact of COVID-19 on 301 female fertility. 

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene

The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease

Angiotensin II revisited: new roles in inflammation, immunology and aging

Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system

Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis

Molecular characterization and regulation of the angiotensin-converting enzyme type 2/angiotensin-(1-7)/MAS receptor axis during the ovulation process in cattle

Gonadotropin stimulation increases the expression of angiotensin-(1-7) and MAS receptor in the rat ovary

Angiotensin-(1-7) induces ovulation and steroidogenesis in perfused rabbit ovaries

Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary

Angiotensin-(1-7): a novel peptide in the ovary

Evidence that angiotensin-(1-7) is an intermediate of gonadotrophin-induced oocyte maturation in the rat preovulatory follicle

The role of angiotensin II in the early stages of bovine ovulation

Saralasin-induced inhibition of ovulation in the in vitro perfused rat ovary is not replicated by the angiotensin II type-2 receptor antagonist PD123319

Angiotensin-(1-7) in human follicular fluid correlates with oocyte maturation

Ovulation: Parallels With Inflammatory Processes

Autopsy of COVID-19 patients in China

Chemokine Ligand 20: A Signal for Leukocyte Recruitment During Human Ovulation?

Gelatinases and their inhibitors during human ovulation: increased expression of tissue inhibitor of matrix mtalloproteinase-1

Coordinated Regulation Among Progesterone, Prostaglandins, and EGF-Like Factors in Human Ovulatory Follicles

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method

Angiogenesis in the primate ovulatory follicle is stimulated by luteinizing hormone via prostaglandin E2

An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling

Dynamics of the transcriptome in the primate ovulatory follicle

Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells

The SARS-CoV-2 receptor, angiotensinconverting enzyme 2, is required for human endometrial stromal cell decidualization

Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels

Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2

Involvement of ACE2/Ang-(1-7)/MAS1 Axis in the Regulation of Ovarian Function in Mammals

Role of angiotensin in ovarian follicular development and ovulation in mammals: a review of recent advances

Role of the angiotensin II system in regulation of ovulation and blood flow in the rat ovary

Human eggs, zygotes, and embryos express the receptor angiotensin 1-converting enzyme 2 and transmembrane serine protease 2 protein necessary for severe acute respiratory syndrome coronavirus 2 infection

Does COVID-19 infection influence patients' performance during IVF-ET cycle?: an observational study

Kaleidoscope Database (http://okdb.appliedbioinfo.net) was redrawn. This dataset was based on 370 microarray data using immature mice that were injected with HMG (FSH+LH activity) and 48 h later 371